Related by context. All words. (Click for frequent words.) 66 rFSH 64 adenoma recurrence 64 μg liter 64 serum concentrations 64 corticosteroid dose 64 glomerular filtration 64 serum aminotransferase levels 64 fetal malformations 63 endometrial thickness 63 plasma cortisol 63 lactate dehydrogenase 63 morphometric vertebral fractures 63 Kaplan Meier 63 serum estradiol 63 leukocyte count 63 GnRH antagonist 63 attain statistical significance 63 aspartate aminotransferase AST 63 foveal thickness 63 prospectively stratified 63 hMG 63 intact parathyroid hormone 63 mammographic density 62 Kaplan Meier estimates 62 Insulin sensitivity 62 HBeAg seroconversion 62 clomiphene citrate 62 symptomatic intracranial hemorrhage 62 maternal serum 62 DHEA supplementation 62 lactate dehydrogenase LDH 62 estimated glomerular filtration 62 Primary endpoints 62 albumin excretion 62 Hb A1C 62 PSA nadir 62 GnRH agonist 62 hematological parameters 62 HER2 expression 62 biochemical relapse 62 circulating lymphocytes 62 preoperative PSA 62 ovulatory 62 serum calcium levels 62 lumbar spine BMD 62 neutrophil counts 62 Lp PLA 2 62 histological subtype 62 anagrelide 61 endometrial carcinoma 61 inflammatory biomarkers 61 mm ³ 61 corifollitropin alfa 61 prospectively defined 61 CRp 61 parous women 61 CD4 + cell 61 postmenopausal hormones 61 angiographic restenosis 61 antiandrogen 61 ± SEM 61 reduce serum phosphate 61 β blockers 61 multiple gestations 61 Kaplan Meier analysis 61 aminotransferase 61 anovulation 61 A1c levels 61 hemoglobin Hb 61 estimated GFR 61 serum triglycerides 61 Serum concentrations 61 intima media thickness 61 multivariate Cox 61 sFlt 1 61 STRIDE PD 61 LV dysfunction 61 serum urate levels 61 bolus dose 61 Index CDAI 61 pCR 61 SCr 61 steroid dexamethasone 61 umbilical artery 61 hemodilution 61 plasma triglycerides 61 leukocyte counts 61 spontaneous preterm delivery 61 elevated transaminases 61 albumin excretion rate 61 renal cysts 60 HOMA IR 60 lymphocytosis 60 Heavy menstrual bleeding 60 confidence intervals CIs 60 relapsed MM 60 recurrent miscarriage 60 CCyR 60 Tasigna prolongs 60 mIU ml 60 #mg dose [002] 60 serum lipid levels 60 ovulatory cycles 60 antibody titer 60 transgene expression 60 atorvastatin #mg 60 edifoligide 60 postoperative mortality 60 pmol L 60 recurrent venous thromboembolism 60 complete cytogenetic response 60 lymphocyte count 60 specific antigen PSA 60 iPTH 60 colorectal adenoma 60 BEXXAR Therapeutic Regimen 60 HbA1C levels 60 SIMPADICO 60 Cardiopulmonary bypass 60 dose Iluvien 60 nucleoside naive patients 60 conjugated equine estrogen 60 recombinant FSH 60 elevated ALT 60 egg retrieval 60 glycated hemoglobin levels 60 mean ± SEM 60 definite stent thrombosis 60 postprocedure 60 serum testosterone 60 plasma folate 60 ARB telmisartan 60 systemic hypotension 60 serum LDL cholesterol 60 IM progesterone 60 SHBG levels 60 peak VO2 60 postintervention 60 spontaneous preterm birth 60 crossclamp 60 LNG IUS 60 anovulatory 60 urinary calcium 60 baseline LDH 60 periprocedural MI 60 vaginal hysterectomy 60 Tumor Response 60 human chorionic gonadotropin hCG 60 dehydroepiandrosterone sulfate 60 serum phosphate 60 treat NNT 60 eosinophil count 60 seropositivity 60 genotypic resistance 60 endometrial hyperplasia 59 transdermal estradiol 59 euthyroid 59 serum bilirubin 59 doxorubicin docetaxel 59 antiandrogens 59 hemoglobin A1c HbA1c 59 Hypotension 59 platelet reactivity 59 fasting plasma 59 corrected QT interval 59 glycosylated hemoglobin HbA1c 59 mutated K ras 59 binary restenosis 59 periprocedural 59 multivariable analysis 59 PASI scores 59 serum urate 59 SUVmax 59 follicle stimulating hormone FSH 59 triiodothyronine 59 LDB CPR 59 fetal chromosomal 59 #ß 59 LV ejection fraction 59 thyrotropin 59 % Confidence Interval 59 serum PTH 59 thyrotropin levels 59 HGPIN 59 Secondary efficacy endpoints 59 inhaled budesonide 59 PSADT 59 Erythropoietic therapies may 59 DAS# remission 59 multivariable Cox 59 μmol L 59 impair fertility 59 umol L 59 gonadotropins 59 Secondary endpoints include 59 HIV HCV coinfected 59 mL/min/#.# m 2 59 serum albumin 59 serum calcium 59 BENICAR HCT 59 CIN2 + 59 Subgroup analysis 59 secondary efficacy endpoint 59 detrusor 59 urine albumin 59 serum CRP 59 cells mcL 59 androgen suppression 59 thyroglobulin 59 tryptase 59 pre eclamptic 59 troponin T 59 luteinising hormone LH 59 skeletal metastases 59 thrombocytopenic 59 calculated creatinine clearance 59 rFVIIa 59 methacholine challenge 59 plasma pharmacokinetics 59 % CI #.#-#.# [008] 59 glomerular filtration rate 59 serum cortisol 59 epoetin alpha 59 nmol liter 59 serum homocysteine 59 prospective multicentre 59 uM 59 abdominal adiposity 59 hip BMD 59 plus medroxyprogesterone acetate 59 apolipoprotein B 59 #β estradiol 59 serum IGF 59 5 HT2C receptor 59 rHuEPO 59 transabdominal 59 virologic failure 59 CI #.#-#.# [001] 59 serum prostate 59 CLA supplementation 59 pg ml 59 T2DM 59 HbA1C 59 thyroid stimulating hormone 58 certolizumab 58 recombinant follicle stimulating 58 follicular phase 58 posttreatment 58 retrograde ejaculation 58 serum HBV DNA 58 perioperative complications 58 hip resurfacing arthroplasty 58 AST ALT 58 singleton pregnancy 58 isoenzyme 58 sustained virological response 58 recurrent VTE 58 oral prednisolone 58 plasma leptin 58 paraprotein 58 hepatic glucose production 58 vasopressor 58 ibandronate 58 Combination antiretroviral therapy 58 inhibin B 58 visceral adiposity 58 clinico pathological 58 serum IgE 58 tumor histology 58 timepoints 58 postoperative chemotherapy 58 DHA supplementation 58 subfertile 58 undetectable HBV DNA 58 TIMP 1 58 dose cohort 58 prostate cancer CaP 58 rhGH 58 luteal phase 58 hormone FSH 58 tumor necrosis 58 Secondary endpoints included 58 Catheter Associated 58 alpha hydroxyprogesterone caproate 58 follicle stimulating hormone 58 RhD negative 58 serum bicarbonate 58 Telintra 58 hypogonadal men 58 postmenopausal hormone 58 HbA 1c levels 58 atherosclerotic progression 58 aneuploidy screening 58 HbF 58 logistic regression analysis 58 CD# upregulation 58 inotropic 58 prolactin levels 58 onset diabetes mellitus 58 annualized relapse 58 alanine aminotransferase ALT 58 MAGE A3 ASCI 58 SERCA2a 58 postmenopausal estrogen 58 neuroregenerative 58 creatine kinase MB 58 #.#/#.# mmHg [001] 58 hypogonadal 58 serum ferritin 58 autoantibody levels 58 HCV replicon 58 cranial irradiation 58 graft occlusion 58 multivariable logistic regression 58 evaluable subjects 58 anogenital distance 58 nonpregnant women 58 pretransplant 58 tracer uptake 58 IQR 58 luteal 58 autologous SCT 58 cardiac contractility 58 ANCOVA 58 mediated dilation 58 inhibin 58 Progestin 58 neurologic progression 58 CK # plasma concentrations 58 daily subcutaneous injections 58 K DOQI 58 #mg/day [001] 58 conditional logistic regression 58 chemosensitivity 58 plasma renin 58 oxyhemoglobin 58 XIENCE V PROMUS Stent 58 cardiovascular hospitalizations 58 estramustine 58 serum lactate 58 preterm neonates 58 dosing cohort 58 repeat paracentesis 58 TMPRSS2 ERG fusion 58 serum glucose 58 lymphocyte counts 58 deep venous thromboses 58 metabolic parameters 58 IVF ICSI 58 MENOPUR 58 sargramostim 58 dose titration 58 Creatinine 58 systemic toxicity 58 bioavailable testosterone 58 protein tyrosine phosphatase 58 TNFalpha 58 sitaxsentan 58 APTIVUS r 58 aPTT 58 CIMZIA TM certolizumab pegol 58 Homocysteine levels 58 Kaplan Meier curve 58 NATRECOR ® 58 IUGR 58 Cmax 58 symptomatic VTE 58 acromegalic patients 57 echocardiographic parameters 57 carotid IMT 57 NIHSS 57 GnRH agonists 57 posttransplant 57 infarct size 57 coronary revascularization 57 plasma HCV RNA 57 salivary flow 57 serum testosterone levels 57 dose dependently 57 ADCS CGIC 57 glycated hemoglobin HbA1c 57 lanthanum carbonate 57 bivariate analysis 57 haematologic 57 Visual Analogue Scale VAS 57 atheroma volume 57 Kaplan Meier survival 57 exogenous insulin 57 nonvertebral fracture 57 maximal dose 57 hematopoietic cancers 57 confirmatory clinical 57 plasma renin activity 57 Serum creatinine 57 QTc prolongation 57 preeclamptic 57 ertapenem 57 antidiabetic medication 57 nadroparin 57 SGPT 57 EGFR HER2 57 hemoglobin hematocrit 57 cervicitis 57 degranulation 57 peg interferon 57 IOP lowering 57 μg kg 57 sperm motility 57 octreotide LAR 57 urinary albumin excretion 57 mucosal healing 57 serum lipid 57 Hematocrit 57 cells μL 57 meta regression 57 GI bleeds 57 intravaginal ejaculatory latency 57 pT3 57 prostanoid 57 sub maximal 57 #mg/day [002] 57 salmeterol fluticasone propionate 57 intraventricular hemorrhage 57 Crohn Disease Activity 57 MTT assay 57 creatine kinase CK 57 mitoxantrone chemotherapy 57 #mg/m# [001] 57 recurrent UTI 57 dietary carbohydrate 57 ovarian hyperstimulation syndrome OHSS 57 tumor regressions 57 Kaplan Meier method 57 immunotoxicity 57 hematologic toxicity 57 monoinfected patients 57 concomitant medications 57 ug dose 57 pharmacodynamic effects 57 ABCB1 57 leiomyomas 57 EBMT criteria 57 CHD mortality 57 CVD mortality 57 thromboxane A2 57 CHAMPION PCI 57 serum parathyroid hormone 57 ovulation induction 57 postoperative morbidity 57 lipoprotein Lp 57 mg/m2 dose 57 hepatic enzyme 57 tryptophan depletion 57 IU ml 57 statistical significance p 57 CYT# QbG# 57 intraocular pressure IOP 57 triglyceride concentration 57 intraobserver 57 cobiprostone 57 selective modulator 57 cystectomy 57 galiximab 57 androgen deprivation 57 Cardiorespiratory fitness 57 Ejection Fraction 57 oral antidiabetic medication 57 REMINYL ® 57 mRS 57 ovarian stimulation 57 abacavir lamivudine 57 menstrual bleeding 57 DLTs 57 atherosclerotic lesion 57 DAS# CRP 57 kidney allograft 57 triacylglycerol 57 plasma lipid 57 RRM1 57 #μg [001] 57 tertile 57 #beta 57 ejection fractions 57 perioperative mortality 57 % CI #.#-#.# [005] 57 Stent thrombosis 57 left ventricular diastolic 57 μg L 57 budesonide foam 57 ELBW infants 57 hemoglobin concentration 57 VT VF 57 endogenous hormones 57 Angiotensin Converting Enzyme 57 median CD4 57 CK MB 57 N telopeptide 57 Suicidal ideation 57 growth hormone secretion 57 reinfarction 57 AMOR IPAT 57 ERalpha 57 serum potassium levels 57 chlamydial infection 57 CR nPR 57 microg 57 flutamide 57 tryptophan hydroxylase 57 hemoglobin A1c levels 57 IFN beta 57 monocyte chemoattractant protein 57 intratumoral 57 postoperative complication 57 ALT flares 57 fosamprenavir 57 corpus luteum 57 MCF7 57 malondialdehyde MDA 57 advanced adenoma 57 NNRTI resistance 57 Wistar rats 57 multivariate adjustment 57 odds ratios ORs 57 LAB GHRH 57 Decitabine 57 hCG human chorionic 57 polycythemia vera essential thrombocythemia 57 QTc 57 metabolite concentrations 57 nonfatal MI 57 MDRD 57 transcranial Doppler ultrasound 57 alteplase 57 severe exacerbations 57 microvessel density 57 endoscopic remission 57 multiple logistic regression 57 Univariate analysis 57 Fas ligand 57 anemia hemoglobin 57 clomipramine 57 eplerenone 57 mL kg 57 ml kg 57 ritonavir boosted lopinavir 57 Scale EDSS score 57 IELT 57 liver histology 57 serum uric acid 57 rtPA 57 fructosamine 57 ipsilateral stroke 57 NO synthase 57 PlGF 57 HIV RNA 57 NF kappaB activation 57 normal ULN 57 DEXA scans 57 creatinine levels 57 transaminase levels 56 linoleic acid LA 56 ALISTA 56 bovine thrombin 56 plasminogen activator inhibitor 56 oestradiol 56 virological response 56 intra uterine 56 bivariate 56 achieved ACR# 56 PROCHIEVE 8 56 NIHSS score 56 ug kg 56 parasitemia 56 MADIT II 56 erection hardness 56 induced phosphorylation 56 neurocognitive function 56 CsA 56 RBP4 levels 56 lipid lowering therapy 56 weekly subcutaneous injections 56 serum phosphate levels 56 hepatic insulin sensitivity 56 Non inferiority 56 nonnucleoside reverse transcriptase inhibitors 56 aminotransferases 56 oxycodone CR 56 mm Hg diastolic 56 HSCT 56 proton MR spectroscopy 56 GP IIb IIIa 56 WOMAC pain 56 CIMZIA ™ 56 renal flares 56 erythropoietic 56 hormone binding globulin 56 endometriosis ovarian cysts 56 abdominal circumference 56 HPA axis suppression 56 extubation 56 myeloperoxidase 56 folate supplementation 56 Postoperative complications 56 dosing frequency 56 multivariable adjusted 56 BENICAR 56 riociguat 56 platelet dysfunction 56 Inhibin B 56 brachial artery flow 56 TURBT 56 â ‰ ¥ 56 carotid plaque 56 progression TTP 56 suppressing ovulation 56 triglyceride concentrations 56 equimolar 56 ovarian hyperstimulation 56 mmol kg 56 postoperative AF 56 serum HCV RNA 56 LDL HDL 56 mL/min/#.# m2 56 p = #.# [003] 56 vasoactive 56 lymph node metastasis 56 cerebral microbleeds 56 HER2 overexpression 56 DES implantation 56 ß blockers 56 histologic subtype 56 hepatorenal syndrome 56 dose escalation phase 56 mTOR inhibitors 56 ventricular remodeling 56 thyroid stimulating hormone TSH 56 cyclic AMP cAMP 56 nondiabetic patients 56 biochemical recurrence 56 hepatectomy 56 unmeasured confounding 56 thromboembolism 56 thrombotic complications 56 HIV seroconversion 56 PREVENT IV 56 testosterone secretion 56 overt hypothyroidism 56 CR CRu 56 alanine aminotransferase 56 Akt activation 56 serum potassium 56 severe neutropenia 56 ADCS ADL 56 sirolimus eluting stents 56 CIMZIA TM 56 prespecified secondary 56 airway responsiveness 56 TDF FTC 56 elevated creatinine 56 mg BID dose 56 BYSTOLIC 56 rebleeding 56 dopamine D2 receptor 56 K ras mutations 56 serum PSA 56 ATACAND 56 logistic regression analyzes 56 gadolinium enhanced 56 serum retinol 56 tHcy 56 detectable HCV RNA 56 microbiologically evaluable 56 vaginal progesterone gel 56 Main Outcome Measure 56 OGTT 56 #mmHg [001] 56 logistic regression model 56 isoprostane 56 PLX STROKE targeting 56 Myelosuppression 56 papillary renal cell carcinoma 56 irbesartan 56 Allogeneic 56 cortisol secretion 56 ovarian carcinoma 56 oocyte retrieval 56 ERK activation 56 vidofludimus 56 Solazed 56 achieved statistical significance 56 piperacillin tazobactam 56 receptor blocker 56 PCWP 56 intravenous bisphosphonates 56 pharmacokinetic parameters 56 REYATAZ r arm 56 κ 56 afterload 56 #beta HSD1 56 hemodynamic variables 56 #μg [002] 56 CDI recurrence 56 serum triglyceride levels 56 MMSE score 56 anti Mullerian hormone 56 pg mL 56 QTcF 56 tertiles 56 ABC/3TC 56 BCIRG 56 antiangiogenic therapy 56 osteoblast 56 hyperinsulinemic euglycemic clamp 56 LB# [003] 56 liver transplant recipients 56 CYP#D# inhibitor 56 TEAEs 56 cytoreduction 56 VA# [002] 56 APOC3 56 abdominal subcutaneous fat 56 Viral load 56 cEVR 56 anthropometric measures 56 multivariable adjustment 56 nucleotide substitutions 56 fraction LVEF 56 intermittent dosing 56 urinary BPA 56 cerebral oxygen saturation 56 mesalamine granules 56 steroidogenesis 56 androgen hormone 56 Follicle Stimulating Hormone 56 lipid lowering drugs 56 protease inhibitor mutations 56 abnormal cytology 56 hepatic resection 56 SLNB 56 AUC0 56 desvenlafaxine succinate 56 CIN3 56 Solid Tumors RECIST 56 #dhTxB# 56 conjugated estrogens 56 ATV RTV 56 plasma fibrinogen 56 heterozygotes 56 adrenal suppression 56 urate lowering therapy 56 nanograms milliliter 56 QT QTc 56 scintigraphic 56 intrauterine insemination IUI 56 mmol l 56 CC genotype 56 Estradiol 56 nonadherence 56 orchiectomy 56 d dimer 56 QTc intervals 56 serum sodium 56 fasting triglycerides 56 androgen blockade 56 prostate carcinoma 56 mg kg dose 56 pelvic lymphadenectomy 56 gonadotropin 56 thyroid carcinoma 56 chemoradiation therapy 56 highest tertile 56 multivariate analyzes 56 pharmacokinetic characteristics 56 CYP #D# 56 sitosterol 56 Y BOCS 56 ischemia driven 56 heFH 56 debulking surgery 56 PROMACTA 56 treatment naive genotype 56 thromboembolic 56 GG genotype 56 urinary iodine 56 atypical ductal hyperplasia 56 sUA 56 renoprotective 56 pretest probability 56 progestogen 56 oral hypoglycemic agents 56 vastus lateralis 56 cystoscopic 56 Pharmacokinetic parameters 56 Ceplene/IL-2 56 Neuropsychiatric Inventory NPI 56 HIF 1a 56 GH IGF 56 serum creatinine levels 56 #Gy 56 polyp recurrence 56 glutamate glutamine 56 homocysteine concentrations 56 paricalcitol 56 enzyme inhibition 56 Prolactin 56 intravascular hemolysis 56 multivariate logistic regression 56 sotalol 56 serum vitamin D 56 NNT = 56 intestinal permeability 56 antiangiogenic agent 56 Platelet counts 56 4mg/kg 56 pDC 56 regression coefficient 56 beta blocker therapy 56 antiretroviral naïve 56 Microalbuminuria 55 Gonadotropin 55 hsCRP levels 55 Am J Cardiol 55 allergic airway inflammation 55 FDG uptake 55 CLINICAL PHARMACOLOGY 55 PEG IFN 55 Active Ulcerative Colitis 55 preimplantation 55 prednisone prednisolone 55 baroreceptor 55 #.#ng/ml 55 Score DAS# 55 hematologic abnormalities 55 graft dysfunction 55 APEX AMI 55 colorectal carcinoma 55 urinary N telopeptide 55 Cytogenetic 55 Retrograde ejaculation 55 log# reduction 55 adiponectin concentrations 55 SOX9 55 transurethral 55 mitochondrial respiration 55 partial thromboplastin 55 FXIII 55 GSTP1 55 beta adrenergic receptor 55 progestagen 55 IL 1ß 55 retrospective observational study 55 Skin sterol 55 lowest tertile 55 ribavirin therapy 55 ALT elevation 55 hormone estradiol 55 ZFP TF 55 #mg dose [003] 55 Unstable Angina 55 endometrial biopsy 55 triacylglycerols 55 carotid intima media 55 cardiac dysfunction 55 rosuvastatin #mg 55 #OHD 55 cecal intubation 55 ARCOXIA 55 Cardiotoxicity 55 transcriptional profiles 55 PASI score 55 tipranavir r 55 covariate 55 tibolone 55 IGFBP 55 Zemplar Capsules 55 CDAI 55 maximal aerobic capacity 55 carotid artery intima media 55 prolactin elevation 55 HbA 1c 55 IFN g 55 serum uric acid sUA 55 creatinine ratio 55 locoregional recurrence 55 concentration Cmax 55 HepG2 cells 55 Androxal TM 55 LHRH agonists 55 unfractionated heparin UFH 55 biventricular repair 55 retransplantation 55 intracranial hemorrhage ICH 55 gastric pH 55 intima media thickness IMT 55 E selectin 55 polytherapy 55 macroalbuminuria 55 gestational hypertension 55 ANCHOR trial 55 colorectal cancer incidence 55 Response Evaluation Criteria 55 serum insulin 55 cilostazol 55 ALT elevations 55 plasma creatinine 55 timepoint 55 Gestational age 55 thyroid hormone levels 55 carotid stenosis 55 hypoglycaemic episodes 55 Flu Cy 55 glycolytic 55 moderately emetogenic 55 LHRH agonist 55 CD4 + T lymphocytes 55 chorioamnionitis 55 underwent surgical resection 55 #.#mg/kg [002] 55 microglial activation 55 mg/m2/day 55 NHANES III 55 5 Fluorouracil 55 viral titers 55 luteinizing hormone LH 55 cardiac perfusion 55 TOP2A 55 NIH CPSI 55 plasma homocysteine 55 syngeneic 55 lanreotide 55 glycogen synthesis 55 pyridostigmine 55 potently inhibited 55 doxorubicin cyclophosphamide 55 baseline HbA1c 55 rt PA 55 progesterone receptor negative 55 SHBG 55 p# activation 55 varicoceles 55 nonfasting triglyceride levels 55 Intervention Trial 55 BMD measurements 55 pulmonary arterial 55 systemic corticosteroid 55 pmol liter 55 spirometric 55 intravenous dosing 55 carotid artery stenting CAS 55 PSMA ADC 55 IFN α 55 univariate analyzes 55 myocardial infarctions MIs 55 Febrile neutropenia 55 metastatic malignant 55 hepatic enzymes 55 testicular tumors 55 oral methylnaltrexone 55 abnormal lipid 55 clomiphene 55 soluble CD# 55 interstitial brachytherapy 55 mIU L 55 Solid Tumors criteria 55 urate lowering 55 atherothrombotic 55 Monocyte 55 hyperphenylalaninemia HPA due 55 venlafaxine XR 55 ovarian follicles 55 external genital lesions 55 ritonavir boosted 55 reactogenicity 55 virological failure 55 genital herpes infections 55 Dose escalation 55 tumorigenicity 55 busulfan 55 nonobese 55 ACR# responses 55 serotonin norepinephrine 55 intraclass correlation coefficient 55 antitumor effect 55 androgen ablation 55 maximally tolerated dose 55 Parathyroid hormone 55 q#d 55 VEGF expression 55 glulisine 55 hydroxy vitamin D 55 ug ml 55 neurodevelopmental outcome 55 μg dL 55 gemtuzumab ozogamicin 55 aminotransferase levels 55 elevated TSH 55 postoperative hemorrhage 55 samalizumab 55 contractility